Analysts forecast that Inogen Inc (NASDAQ:INGN) will report sales of $107.55 million for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Inogen’s earnings. The highest sales estimate is $110.68 million and the lowest is $104.10 million. Inogen reported sales of $97.24 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.6%. The business is scheduled to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that Inogen will report full-year sales of $409.24 million for the current year, with estimates ranging from $407.57 million to $411.30 million. For the next financial year, analysts anticipate that the firm will report sales of $470.86 million, with estimates ranging from $458.56 million to $482.90 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Inogen.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). Inogen had a return on equity of 15.59% and a net margin of 12.56%. The company had revenue of $90.20 million during the quarter, compared to analysts’ expectations of $89.69 million. During the same quarter in the previous year, the company earned $0.48 EPS. The business’s quarterly revenue was up 14.1% compared to the same quarter last year.

Several research firms recently issued reports on INGN. Zacks Investment Research cut Inogen from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. BidaskClub cut Inogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 13th. Needham & Company LLC reiterated a “buy” rating and set a $191.00 target price on shares of Inogen in a research report on Tuesday, April 9th. JPMorgan Chase & Co. cut Inogen from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $175.00 to $72.00 in a research report on Wednesday, May 8th. Finally, Stifel Nicolaus cut their target price on Inogen from $160.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $121.60.

NASDAQ:INGN opened at $66.11 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.35 and a quick ratio of 6.70. Inogen has a 12-month low of $64.01 and a 12-month high of $287.79. The stock has a market cap of $1.45 billion, a P/E ratio of 28.74, a price-to-earnings-growth ratio of 2.72 and a beta of 1.39.

Large investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Inogen during the first quarter worth about $25,000. Fifth Third Bancorp lifted its stake in shares of Inogen by 115.0% in the 1st quarter. Fifth Third Bancorp now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 153 shares during the last quarter. Hanson McClain Inc. bought a new stake in shares of Inogen in the 1st quarter valued at approximately $50,000. South Dakota Investment Council bought a new stake in shares of Inogen in the 4th quarter valued at approximately $87,000. Finally, First Mercantile Trust Co. bought a new stake in shares of Inogen in the 4th quarter valued at approximately $99,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with's FREE daily email newsletter.